CLAIMS

1. An isolated antibody molecule that specifically binds to the exosite 1 region of thrombin, in which the antibody molecule comprises a VH domain comprising a HCDR1, HCDR2 and HCDR3 having the sequences of SEQ ID NOs 3, 4 and 5, respectively and a VL domain comprising an LCDR1, LCDR2 and LCDR3 having the sequences of SEQ ID NOs 7, 8 and 9 respectively, in which LCDR1 having the sequence of SEQ ID NO: 7 may have a glycosylation site mutated out with a substitution at an amino acid residue corresponding to N28 or S30 in SEQ ID NO: 6.

2. An antibody molecule according to Claim 1 that inhibits thrombin activity.

3. An antibody molecule according to Claim 2 which causes minimal inhibition of haemostasis and/or causes minimal bleeding.

4. An antibody molecule according to Claim 2 or 3 which does not inhibit haemostasis and/or does not cause bleeding.

5. An antibody molecule according to any preceding claim, in which the antibody molecule comprises a VH domain having the amino acid sequence of SEQ ID NO: 2.

6. An antibody molecule according to any preceding claim, in which the antibody molecule comprises a VL domain having the amino acid sequence of SEQ ID NO: 6 or the amino acid sequence of SEQ ID NO: 6 in which a glycosylation site is mutated out with a substitution at an amino acid residue corresponding to N28 or S30 in SEQ ID NO: 6.

7. An antibody molecule according to any preceding claim comprising a VH domain comprising a HCDR1, HCDR2 and HCDR3 having the sequences of SEQ ID NOs 3, 4 and 5, respectively, and a VL domain comprising a LCDR1, LCDR2 and LCDR3 having the sequences of SEQ ID NOs 7, 8 and 9, respectively.

8. An antibody molecule according to Claim 7 comprising a VH domain having the amino acid sequence of SEQ ID NO: 2 and a VL domain having the amino acid sequence of SEQ ID NO: 6.

9. An antibody molecule according to any of Claims 1 to 6, in which a glycosylation site is mutated out with a substitution at an amino acid residue corresponding to S30 in SEQ ID NO: 6.

10. An antibody molecule according to Claim 9 comprising a VL domain having the amino acid sequence of SEQ ID NO: 6 in which the glycosylation site is mutated out with a substitution at S30.

11. An antibody molecule according to any preceding claim which is a whole antibody.

12. An antibody molecule according to Claim 11 which is an IgA or IgG.

13. An antibody molecule according to any of Claims 1 to 10 which is a monoclonal antibody.

14. An antibody molecule according to any of Claims 1 to 10 which is an antibody fragment.

15. A pharmaceutical composition comprising an antibody molecule according to any preceding claim and a pharmaceutically acceptable excipient.

16. An antibody molecule according to any of Claims 1 to 14 for use in a method of treatment of the human or animal body.

17. An antibody molecule according to any of Claims 1 to 14 for use in a method of treatment of a thrombin-mediated condition.

18. Use of an antibody molecule according to any of Claims 1 to 14 in the manufacture of a medicament for use in treating a thrombin-mediated condition.

19. An antibody molecule according to Claim 17 for a use as specified therein or a use according to Claim 18, in which the thrombin-mediated condition is a thrombotic condition.

20. An antibody molecule for a use or a use according to Claim 19, in which the thrombotic condition is thrombosis or embolism.

21. An antibody molecule according to Claim 17 for a use as specified therein or a use according to Claim 18, in which the thrombin-mediated condition is inflammation, infection, tumour growth, tumour metastasis or dementia.